Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) said they received a clinical trial approval for SKB445 from the Center for Drug Evaluation of the National Medical Products Administration on Jan. 20, according to a Monday filing with the Hong Kong Stock Exchange.
SKB445, a new antibody-drug conjugate (ADC) drug, shows promise in treating advanced solid tumors, demonstrating efficacy and safety in preclinical studies using OptiDCTM technology, the filing added.
The pharmaceutical company's shares were up by 1% in recent trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。